OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.

Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed encouraging with regard to moving this concept further in the clinic".

The Company intends to submit these findings to a peer-reviewed scientific journal and is expected to announce further top-line results soon, including the direction of future clinical development of VXM01 and its platform.

Expected Highlights

While the full results will be presented as soon as the publication process allows, the manuscript is expected to include:

VXM01, both as monotherapy and in combination therapy proved to be safe and well tolerated, with no dose-limiting toxicities or high-grade treatment-related adverse event observed. These findings support the excellent safety profile seen in prior studies in subjects with pancreatic adenocarcinoma

Successful activation of patients' immune system against the target

Indication of dose-dependent immunological activity

Supporting biomarker findings consistent with the proposed mechanism of action.

"We are excited by the encouraging results of these glioblastoma studies, adding to our prior evaluations in pancreatic cancer. The data from both trials give further credibility to VXM01, as well as to the oral DNA vaccine platform itself, as an approach to active immunization against a chosen target. We look forward to sharing the full dataset with the scientific community as we continue advancing VXM01 as a unique approach for the treatment of multiple cancer indications." said Dr. Andreas Niethammer, CEO of Vaximm AG.